Rozanolixizumab

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myasthenia Gravis

Conditions

Myasthenia Gravis

Trial Timeline

Dec 1, 2025 → Oct 15, 2027

NCT ID

NCT07246564

About Rozanolixizumab

Rozanolixizumab is a approved stage product being developed by UCB for Myasthenia Gravis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07246564. Target conditions include Myasthenia Gravis.

What happened to similar drugs?

0 of 20 similar drugs in Myasthenia Gravis were approved

Approved (0) Terminated (2) Active (18)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄tacrolimus + placeboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05014724	Pre-clinical	Completed	—	—	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07465289	Phase 3	Recruiting	Jul 27, 2026	Jan 23, 2031	Ocular Myasthenia Gravis
NCT07246564	Approved	Recruiting	Dec 1, 2025	Oct 15, 2027	Myasthenia Gravis
NCT06720714	Phase 1	Completed	Dec 3, 2024	May 12, 2025	Healthy Participants
NCT06540144	Phase 3	Recruiting	Oct 8, 2024	Aug 17, 2027	Generalized Myasthenia Gravis
NCT06149559	Phase 2/3	Recruiting	Jun 14, 2024	Aug 17, 2026	Generalized Myasthenia Gravis
NCT05681715	Phase 3	Completed	Apr 17, 2023	Apr 23, 2024	Generalized Myasthenia Gravis
NCT05643794	Phase 2	Completed	Dec 21, 2022	Jul 9, 2024	Fibromyalgia
NCT05063162	Phase 3	Active	Feb 2, 2022	Jul 1, 2027	Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
NCT04828343	Phase 1	Completed	Apr 22, 2021	Apr 11, 2022	Healthy Study Participants
NCT04650854	Phase 3	Completed	Feb 3, 2021	Jan 25, 2024	Generalized Myasthenia Gravis
NCT04596995	Phase 3	Terminated	Jan 6, 2021	Dec 21, 2022	Primary Immune Thrombocytopenia
NCT04224688	Phase 3	Terminated	Jun 3, 2020	May 5, 2022	Primary Immune Thrombocytopenia
NCT04200456	Phase 3	Terminated	Jan 31, 2020	Apr 27, 2022	Primary Immune Thrombocytopenia
NCT04124965	Phase 3	Completed	Oct 29, 2019	Sep 1, 2021	Generalized Myasthenia Gravis
NCT04051944	Phase 2	Completed	Aug 21, 2019	Nov 10, 2021	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT03971422	Phase 3	Completed	Jun 3, 2019	Oct 26, 2021	Generalized Myasthenia Gravis
NCT03861481	Phase 2	Completed	Mar 26, 2019	Mar 31, 2021	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Competing Products

20 competing products in Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44